335255-33-9

Basic information

• Product Name: N-(3-AMino[1,1'-biphenyl]-4-yl)-carbaMic Acid tert-Butyl Ester
• Synonyms: N-(3-AMino[1,1'-biphenyl]-4-yl)-carbaMic Acid tert-Butyl Ester;tert-butyl (3-amino-[1,1'-biphenyl]-4-yl)carbamate;N-(3-aminobiphenyl-4-yl)carbamic acid 1,1-dimethylethyl ester;tert-butyl 3-aminobiphenyl-4-ylcarbamate
• CAS NO: 335255-33-9
• Molecular Formula: C₁₇H₂₀N₂O₂
• Molecular Weight: 284.3529
• Product Categories: Amines, Aromatics, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 335255-33-9.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 400.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.155±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Dichloromethane, Methanol
• PKA: 13.24±0.70(Predicted)
• CAS DataBase Reference: N-(3-AMino[1,1'-biphenyl]-4-yl)-carbaMic Acid tert-Butyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-AMino[1,1'-biphenyl]-4-yl)-carbaMic Acid tert-Butyl Ester(335255-33-9)
• EPA Substance Registry System: N-(3-AMino[1,1'-biphenyl]-4-yl)-carbaMic Acid tert-Butyl Ester(335255-33-9)

Safety Data

• Hazardous Substances Data: 335255-33-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

N-(3-Amino[1,1'-biphenyl]-4-yl)-carbamic Acid tert-Butyl Ester is a reactant used in the optimization of selective HDAC1/HDAC2 inhibitor, preparation of non-competitive metabotropic glutamate receptor 2/3 antagonists

Upstream product

• 98-80-6 phenylboronic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 327046-79-7 tert-butyl (4-bromo-2-nitrophenyl)carbamate 
• 875-51-4 4-Bromo-2-nitroaniline 
• 335254-77-8 tert-butyl (3-nitro-[1, 1'-biphenyl]-4-yl)carbamate 

Downstream Products

• 335257-66-4 8-Phenyl-4-thiophen-2-yl-1,3-dihydro-benzo[b][1,4]diazepin-2-one 
• 335256-67-2 {3-[3-(3-chloro-thiophen-2-yl)-3-oxo-propionylamino]-biphenyl-4-yl}-carbamic acid tert.-butyl ester 
• 335257-81-3 8-Phenyl-4-(3-trifluoromethyl-phenyl)-1,3-dihydro-benzo [b][1,4]diazepin-2-one 
• 335257-68-6 4-(3-Chloro-phenyl)-8-phenyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one 
• 335256-52-5 {3-[3-(3-Azido-phenyl)-3-oxo-propionylamino]-biphenyl-4-yl}-carbamic Acid tert.-Butyl Ester 
• 937729-01-6 C₄₀H₄₆N₆O₄ 
• 936706-62-6 C₃₆H₃₉N₅O₅ 
• 1609390-92-2 C₃₂H₃₆N₄O₅ 
• 1609390-89-7 C₃₁H₃₅N₅O₄ 
• 1609390-86-4 C₃₁H₃₅N₅O₄ 
• 1609390-85-3 C₃₄H₃₆N₄O₄ 
• 1609389-57-2 N-(4-amino-[1,1'-biphenyl]-3-yl)-8-cyclopropyl-7-morpholinoquinoline-3-carboxamide 
• 1609390-80-8 C₃₉H₄₅N₅O₅ 
• 1609389-55-0 N-(4-amino-[1,1'-biphenyl]-3-yl)-8-cyclopropyl-7-(piperazin-1-yl)isoquinoline-3-carboxamide 

Relevant articles and documents

Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class?I Selective HDAC Inhibitors

Herein we report the structure-activity and structure-physicochemical property relationships of a series of class I selective ortho-aminoanilides targeting the “foot-pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with a set of HDACi related to tacedinaline (CI-994) and evaluated their solubility, lipophilicity (log D7.4) and inhibition of selected HDAC isoforms. Subsequently, we selected the most promising “capless” HDACi and transferred its ZBG to our previously published scaffold featuring a peptoid-based cap group. The resulting hit compound 10 c (LSH-A54) showed favorable physicochemical properties and is a potent, selective HDAC1/2 inhibitor. The following evaluation of its slow binding properties revealed that LSH-A54 binds tightly to HDAC1 in an induced-fit mechanism. The potent HDAC1/2 inhibitory properties were reflected by attenuated cell migration in a modified wound healing assay and reduced cell viability in a clonogenic survival assay in selected breast cancer cell lines.

URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES

The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autos

Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups

As a hot topic of epigenetic studies, histone deacetylases (HDACs) are related to lots of diseases, especially cancer. Further researches indicated that different HDAC isoforms played various roles in a wide range of tumor types. Herein a novel series of HDAC inhibitors with isatin-based caps and o-phenylenediamine-based zinc binding groups have been designed and synthesized through scaffold hopping strategy. Among these compounds, the most potent compound 9n exhibited similar if not better HDAC inhibition and antiproliferative activities against multiple tumor cell lines compared with the positive control entinostat (MS-275). Additionally, compared with MS-275 (IC50 values for HDAC1, 2 and 3 were 0.163, 0.396 and 0.605?μM, respectively), compound 9n with IC50 values of 0.032, 0.256 and 0.311?μM for HDAC1, 2 and 3 respectively, showed a moderate HDAC1 selectivity.